OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Delayed Deutsche Boerse AG 07:14:09 2024-05-31 am EDT | ||
| 5.45 EUR | +2.25% |
|
| 3 months | +65.53% | ||
| 6 months | +63.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 5.45 | +2.25% |
| 24-05-30 | 5.33 | +2.11% |
| 24-05-29 | 5.22 | -1.88% |
| 24-05-28 | 5.32 | -6.83% |
| 24-05-27 | 5.71 | +0.71% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 07:14 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD8WD0 |
| ISIN | DE000SD8WD02 |
| Date issued | 2021-03-04 |
| Strike | 7,469 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.11 € |
|---|---|
| Lowest since issue | 0.37 € |
| Spread | 0.01 € |
| Spread % | 0.18% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
153.3
USD
Average target price
172
USD
Spread / Average Target
+12.23%
- Stock Market
- Certificates
- Certificat
